Skip to Main Content

A tiny startup with just five employees and one investor inked a deal with one of the largest pharmaceutical companies in the world this week — and while the deal itself is conventional, it got off to a decidedly unconventional start.

GO Therapeutics, based at Cambridge, Mass.’s LabCentral incubator, announced on Tuesday it had licensed antibodies for a particular cancer target to Roche. And rather than pitching themselves, GO’s CEO and co-founder Constantine Theodoropulos said, Roche came to them.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED